Patents Assigned to RESURGE THERAPEUTICS INC.
  • Treatments for benign prostatic hyperplasia
    Patent number: 11974979
    Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.
    Type: Grant
    Filed: April 22, 2022
    Date of Patent: May 7, 2024
    Assignee: RESURGE THERAPEUTICS, INC.
    Inventors: Olof Mikael Trollsas, John J. Stankus, Shahram Shawn Gholami
  • System and method for prostate treatment
    Patent number: 11911499
    Abstract: A minimally invasive treatment of benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. A method includes introducing a composition into the prostate to achieve a sustained release of the cytostatic or cytotoxic drug over a period of between about 14 days and 12 months.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: February 27, 2024
    Assignee: Resurge Therapeutics, Inc.
    Inventors: Olof Mikael Trollsas, John J. Stankus, Shahram Shawn Gholami
  • Treating benign prostatic hyperplasia
    Patent number: 11602516
    Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.
    Type: Grant
    Filed: April 22, 2022
    Date of Patent: March 14, 2023
    Assignee: RESURGE THERAPEUTICS INC.
    Inventors: Olof Mikael Trollsas, John J. Stankus, Shahram Shawn Gholami